Shots:  AstraZeneca’s patient-focused immunology vision is reinforced by the EU approval of subcutaneous, self-administered Saphnelo (anifrolimab), offering people with SLE a more convenient option that reduces treatment burden, supports earlier biologic use, and advances the goal of remission beyond symptom control  The new formulation is expected to improve access, uptake, and adherence while easing infusion capacity constraints, with regulatory…